================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
November 6, 2003
------------------------------------------------
Date of Report (Date of earliest event reported)
NPS PHARMACEUTICALS, INC.
------------------------------------------------------
(Exact Name of Registrant as Specified in Its Charter)
Delaware 0-23272 87-0439579
- ------------------------------- ---------------- ----------------------
(State or Other Jurisdiction of (Commission File (I.R.S. Employer
Incorporation) Number) Identification Number)
420 Chipeta Way
Salt Lake City, Utah 84108
----------------------------------------
(Address of principal executive offices)
(801) 583-4939
----------------------------------------------------
(Registrant's telephone number, including area code)
================================================================================
ITEM 12: Results of Operations and Financial Condition
The following information is furnished pursuant to Item 12, "Results of
Operations and Financial Condition." On November 6, 2003, NPS Pharmaceuticals,
Inc. (the "Company") issued a press release announcing the Company's 2003 third
quarter and nine month operating results. The text of the press release is
furnished as Exhibit 99.1 to this Form 8-K.
The information in this Form 8-K and the Exhibit attached hereto shall not
be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of
1934 (the "Exchange Act") or otherwise subject to the liabilities of that
section, nor shall it be deemed incorporated by reference in any filing under
the Securities Act of 1933 or the Exchange Act, except as expressly set forth by
specific reference in such filing.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date: November 6, 2003 NPS PHARMACEUTICALS, INC.
By: /s/ HUNTER JACKSON
---------------------------
Hunter Jackson
CEO, President and Chairman
of the Board
EXHIBIT INDEX
Exhibit
Number Description
------ -----------
99.1 Press Release issued by NPS Pharmaceuticals, Inc. on November 6,
2003 announcing the Company's 2003 third quarter and nine month
operating results.